November 23, 2016 - By Vivian Park
PAREXEL (PRXL)‘s stock was decreased to a Market Perform by analysts at Wells Fargo. PRXL’s Outperform rating is no longer valid.
Out of 5 analysts covering PAREXEL (PRXL), 0 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 0 are positive. $76.0 is the highest target while $62.0 is the lowest. The $67.50 average target is 17.09% above today’s ($57.65) stock price. PAREXEL has been the topic of 5 analyst reports since September 6, 2016 according to StockzIntelligence Inc. The firm has “Hold” rating given on Friday, October 28 by Deutsche Bank. UBS downgraded PAREXEL International Corporation (NASDAQ:PRXL) on Tuesday, September 6 to “Neutral” rating. The rating was downgraded by Robert W. Baird to “Neutral” on Thursday, October 27. As per Thursday, November 17, the company rating was downgraded by First Analysis. As per Friday, November 11, the company rating was downgraded by SunTrust.
About 158,357 shares traded hands. PAREXEL International Corporation (PRXL) has declined 12.36% since April 21, 2016 and is downtrending. It has underperformed by 17.69% the S&P500.
Insitutional Activity: The institutional sentiment decreased to 1 in 2016 Q2. Its down 0.16, from 1.16 in 2016Q1. The ratio fall, as 31 funds sold all PAREXEL International Corporation shares owned while 96 reduced positions. 45 funds bought stakes while 102 increased positions. They now own 46.71 million shares or 2.30% less from 47.81 million shares in 2016Q1.
Aristotle Boston Limited Co holds 156,770 shares or 2.21% of its portfolio. Commonwealth Equity Svcs Incorporated, a Massachusetts-based fund reported 3,363 shares. Moreover, State Bank Of Ny Mellon has 0.02% invested in PAREXEL International Corporation (NASDAQ:PRXL) for 1.03M shares. Trust Department Mb State Bank N A last reported 90,978 shares in the company. Morgan Stanley has 0.01% invested in the company for 386,271 shares. Blackrock Inv Mngmt Ltd Liability Co last reported 0.03% of its portfolio in the stock. Bbva Compass Savings Bank Incorporated last reported 0.12% of its portfolio in the stock. Los Angeles Cap Management Equity Research owns 4,739 shares or 0% of their US portfolio. Clearbridge Limited Liability holds 793,077 shares or 0.06% of its portfolio. Phocas has 0.6% invested in the company for 130,786 shares. Moreover, Reinhart Partners has 0.18% invested in PAREXEL International Corporation (NASDAQ:PRXL) for 28,325 shares. Genesee Valley has 9,656 shares for 0.39% of their US portfolio. Moreover, Franklin Resource has 0.02% invested in PAREXEL International Corporation (NASDAQ:PRXL) for 549,802 shares. Panagora Asset Mgmt Inc accumulated 0.02% or 78,073 shares. The North Carolina-based Carroll Assoc has invested 0% in PAREXEL International Corporation (NASDAQ:PRXL).
Insider Transactions: Since May 24, 2016, the stock had 0 insider purchases, and 4 insider sales for $570,931 net activity. SCHNEIDER ULF I also sold $366,000 worth of PAREXEL International Corporation (NASDAQ:PRXL) shares. Schultz Joshua sold $171,600 worth of stock or 2,500 shares. Saarony Gadi sold $175,125 worth of stock. CALLOW A DANA JR had sold 3,000 shares worth $180,120 on Monday, June 13. Holdener Eduard E. sold $44,086 worth of stock or 700 shares.
PAREXEL International Corporation is a biopharmaceutical outsourcing services company. The company has a market cap of $3.13 billion. The Firm provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology services and products to pharmaceutical, biotechnology and medical device industries. It has a 18.43 P/E ratio. The Company’s divisions include Clinical Research Services (CRS), PAREXEL Consulting Services (PC) and PAREXEL Informatics (PI).
According to Zacks Investment Research, “Parexel International Corporation is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales.”
PAREXEL International Corporation (PAREXEL), incorporated on January 3, 1983, is a biopharmaceutical outsourcing services company. The Firm provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology services and products to pharmaceutical, biotechnology and medical device industries. The Company’s divisions include Clinical Research Services (CRS), PAREXEL Consulting Services (PC) and PAREXEL Informatics (PI).
More notable recent PAREXEL International Corporation (NASDAQ:PRXL) news were published by: Businesswire.com which released: “PAREXEL International Announces $200 Million Accelerated Share Repurchase Program” on November 22, 2016, also Fool.com with their article: “PAREXEL International Corporation’s Q1 Report Flops, Shares Sink As Much As 13%” published on October 27, 2016, Prnewswire.com published: “SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of …” on November 11, 2016. More interesting news about PAREXEL International Corporation (NASDAQ:PRXL) were released by: Businesswire.com and their article: “Bragar Eagel & Squire, P.C. Is Investigating PAREXEL International Corporation …” published on November 14, 2016 as well as Bizjournals.com‘s news article titled: “Parexel loses $160M in value after disclosing possible embezzlement” with publication date: September 01, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Vivian Park